DK0809516T3 - Medicinsk kombination, som er anvendelig til transfektion og ekspression in vivo af exogener - Google Patents

Medicinsk kombination, som er anvendelig til transfektion og ekspression in vivo af exogener

Info

Publication number
DK0809516T3
DK0809516T3 DK96903080T DK96903080T DK0809516T3 DK 0809516 T3 DK0809516 T3 DK 0809516T3 DK 96903080 T DK96903080 T DK 96903080T DK 96903080 T DK96903080 T DK 96903080T DK 0809516 T3 DK0809516 T3 DK 0809516T3
Authority
DK
Denmark
Prior art keywords
exogens
expression
vivo transfection
medical combination
combination useful
Prior art date
Application number
DK96903080T
Other languages
Danish (da)
English (en)
Inventor
Jean-Francois Bach
Michel Perricaudet
Martin Lee
Lucienne Chatenoud
Hedi Haddada
Michelle Webb
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK0809516T3 publication Critical patent/DK0809516T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96903080T 1995-02-14 1996-02-12 Medicinsk kombination, som er anvendelig til transfektion og ekspression in vivo af exogener DK0809516T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
PCT/FR1996/000218 WO1996025177A1 (fr) 1995-02-14 1996-02-12 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (1)

Publication Number Publication Date
DK0809516T3 true DK0809516T3 (da) 2001-12-17

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96903080T DK0809516T3 (da) 1995-02-14 1996-02-12 Medicinsk kombination, som er anvendelig til transfektion og ekspression in vivo af exogener

Country Status (23)

Country Link
US (2) US20030004091A1 (de)
EP (1) EP0809516B1 (de)
JP (1) JPH11500430A (de)
KR (1) KR100402540B1 (de)
AT (1) ATE204481T1 (de)
AU (1) AU717218B2 (de)
BR (1) BR9607310A (de)
CA (1) CA2211039C (de)
CZ (1) CZ258197A3 (de)
DE (1) DE69614668T2 (de)
DK (1) DK0809516T3 (de)
ES (1) ES2163612T3 (de)
FI (1) FI119176B (de)
FR (1) FR2730411B1 (de)
GR (1) GR3036438T3 (de)
HU (1) HU222991B1 (de)
IL (1) IL117116A0 (de)
MX (1) MX9706017A (de)
NO (1) NO320072B1 (de)
PT (1) PT809516E (de)
SK (1) SK282235B6 (de)
WO (1) WO1996025177A1 (de)
ZA (1) ZA961161B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
AU4088697A (en) * 1996-08-26 1998-03-19 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
CA2308017A1 (en) 1997-10-30 1999-05-14 Erik S. Falck-Pedersen A method of inhibiting an immune response to a recombinant vector
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CA2781858C (en) * 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
EP1411770A4 (de) 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
ATE520400T1 (de) * 2002-11-21 2011-09-15 Genzyme Corp Kombination von einem diamidderivat und immunsuppressiva zur unterdrückung der transplantatabstossung
EP1725254A4 (de) * 2004-02-04 2008-02-13 Univ Columbia Anti-cd3 und antigen-spezifische immuntherapie zur behandlung von autoimmunität
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016065A1 (en) * 1992-12-31 1994-07-21 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
AU5965294A (en) * 1993-01-08 1994-08-15 Exemplar Corporation An (in vitro)/(in vivo) method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
ES2163612T3 (es) 2002-02-01
EP0809516B1 (de) 2001-08-22
CA2211039C (fr) 2011-12-06
KR100402540B1 (ko) 2004-05-07
FI973323A0 (fi) 1997-08-13
IL117116A0 (en) 1996-06-18
HUP9800635A3 (en) 2000-12-28
AU717218B2 (en) 2000-03-23
JPH11500430A (ja) 1999-01-12
ATE204481T1 (de) 2001-09-15
KR19980702199A (ko) 1998-07-15
FI119176B (fi) 2008-08-29
MX9706017A (es) 1997-11-29
HU222991B1 (hu) 2004-01-28
FI973323L (fi) 1997-08-13
EP0809516A1 (de) 1997-12-03
CA2211039A1 (fr) 1996-08-22
ZA961161B (en) 1996-08-07
CZ258197A3 (en) 1997-11-12
BR9607310A (pt) 1997-11-25
WO1996025177A1 (fr) 1996-08-22
NO973724D0 (no) 1997-08-13
GR3036438T3 (en) 2001-11-30
DE69614668T2 (de) 2002-06-27
NO320072B1 (no) 2005-10-17
SK282235B6 (sk) 2001-12-03
FR2730411B1 (fr) 1997-03-28
PT809516E (pt) 2002-02-28
HUP9800635A2 (hu) 1998-07-28
US20030004091A1 (en) 2003-01-02
FR2730411A1 (fr) 1996-08-14
DE69614668D1 (de) 2001-09-27
NO973724L (no) 1997-08-13
SK110897A3 (en) 1998-01-14
AU4723896A (en) 1996-09-04
US20040265276A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
DK0809516T3 (da) Medicinsk kombination, som er anvendelig til transfektion og ekspression in vivo af exogener
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
FI970768L (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä riippuvalla vaikuttavalla aineella
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
FI973467A0 (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
MXPA03004913A (es) Usos de genes de mamifero y reactivos relacionados.
DK0556345T3 (da) Retrovirale vektorer,som er egnede til genterapi
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
NO982764L (no) Oppfinnelse og anordning for transdermal anordning for avgivelse av flurbiprofen
CY2396B1 (en) Pharmaceutical composition of fenofibrate with high biological availability and method for preparingsame.
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
IL181695A0 (en) Methods for cultivating cells and propagating viruses
ATE380202T1 (de) Interaktionssystem zur präsentation und entfernung von substanzen
FI961666A7 (fi) Restenosiksen geeniterapia, jossa käytetään adenovirusvektoria
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
ZA97657B (en) Ligand directed enzyme prodrug therapy.
ES2161074T3 (es) Composicion de teñido que contiene una lacasa y procedimientos de teñido de las fibras queratinicas que la utilizan.
NO992577D0 (no) Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel
EP1185306A4 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie
ES2141044A1 (es) Terapia con oxibutinina.
UA25582C2 (uk) Засіб для лікування гематоцитопенічних реакцій теплокровних організмів
IT239614Y1 (it) Siringa salva vita.
JO1897B1 (en) Disposable syringe is used only once and it destroys itself automatically